SCHEMBL2557698

SCHEMBL2557698

O=C1c2ccccc2C(=O)N1C1CCc2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 6/20 0.57
DDB1 Q16531 5/20 0.57
IKZF3 Q9UKT9 2/20 0.57
ALDH1A1 P00352 1/20 0.57
CHRM2 P08172 1/20 0.57
OPRM1 P35372 1/20 0.57
CYP1A2 P05177 1/20 0.57
TSHR P16473 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
HSD11B1 P28845 2/20 0.45
CHRNA7 P36544 1/20 0.44
TNF P01375 1/20 0.43
IL1B P01584 1/20 0.43
TBXA2R P21731 1/20 0.43
IKZF1 Q13422 1/20 0.43
GPR84 Q9NQS5 1/20 0.43
P2RX7 Q99572 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15028540 1.00 CRBN (0.57) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL30703123 1.00 CRBN (0.57) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL1264462 0.90 OPRM1 (0.50) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL30998388 0.90 OPRM1 (0.50) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL1265932 0.90 OPRM1 (0.50) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL2557414 0.84 CRBN (0.65) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL1265365 0.83 CRBN (0.57) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL30998375 0.83 CRBN (0.57) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL1265364 0.83 CRBN (0.57) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL14602355 0.82 OPRM1 (0.49) CRBNDDB1IKZF3ALDH1A1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024013209-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-01-18 WO disclosed
US-9701633-B2 Methods and intermediates useful for the preparation of alpha-branched aryl phthalimides and alpha-branched aryl amines Ripon College (US) 2017-07-11 US disclosed
US-9701633-B2 Methods and intermediates useful for the preparation of alpha-branched aryl phthalimides and alpha-branched aryl amines Ripon College (US) 2017-07-11 US disclosed
US-20160200680-A1 Methods and Intermediates Useful for the Preparation of alpha-Branched Aryl Phthalimides and alpha-Branched Aryl Amines Ripon College 2016-07-14 US disclosed
US-20160200680-A1 Methods and Intermediates Useful for the Preparation of alpha-Branched Aryl Phthalimides and alpha-Branched Aryl Amines Ripon College 2016-07-14 US disclosed
WO-2011121062-A1 COMPOSITION FOR THE TREATMENT OF PERIODONTITIS AND OTHER INFLAMMATORY INFECTIOUS DISEASES VOCKNER HELMUT (AT) 2011-10-06 WO disclosed
US-7893071-B2 Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2011-02-22 US disclosed
US-7893071-B2 Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2011-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160200680-A1 Methods and Intermediates Useful for the Preparation of alpha-Branched Aryl Phthalimides and alpha-Branched Aryl Amines PAH, BCAT1, BCAT2 CRBN 188/4885DDB1 913/4885IKZF3 1326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.